The Company expects that its cash, cash equivalents and short-term investments as of June 30, 2023, will enable it to fund its operating plan into the fourth quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CABA:
- Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
- Cabaletta Bio appoints Tomasello to board of directors
- Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
- Cabaletta Bio initiated with a Buy at Guggenheim
- Biotech Alert: Searches spiking for these stocks today